前向き無作為多施設検討による神秘湯吸入療法とＳｏｄｉｕｍ　Ｃｒｏｍｏｇｌｉｃａｔｅ吸入療法による気管支ぜん息患者治療成績比較検討試験

• 西澤 芳男

  西沢クリニック 京都府立医科大学大学院医学研究科分子病態病理学 滋賀医科大学麻酔学教室

• 西澤 恭子

  大阪成人病センター研究所病理学部門 大阪大学大学院薬学研究科環境病因病態学

• 後藤 グレイシイ・広恵

  大阪大学大学院薬学研究科環境病因病態学

• 吉岡 二三

  吉岡医院

• 野坂 修一

  滋賀医科大学麻酔学教室

• 雨森 保憲

  滋賀医科大学麻酔学教室

• 谷垣 由美子

  滋賀医科大学麻酔学教室

• 永野 富美代

  西沢クリニック

• 山田 まゆみ

  西沢クリニック

• 平田 弥生

  西沢クリニック

• 安田 理絵

  西沢クリニック

• 川田 陽子

  西沢クリニック

• 天方 義邦

  中山報恩会住之江病院

• 伏木 信次

  京都府立医科大学大学院医学研究科分子病態病理学

書誌事項

タイトル別名

• A RANDOMIZED, GROUP-PARALLEL COMPARATIVE TRIAL OF THE SUPPRESSIVE EFFECT OF CHINESE TRADITIONAL MEDICINE, SHEN-MI-TANG (SHIN-PI-TO), COMPARED TO SODIUM ORAMOYLYCATE INHALATION IN IMPROVING SUBJECTIVE AND OBJECTIVE SYMPTOMS IN BRONCHIAL ASTHMATICS

抄録

Shen-mi-tang (Shin-pi-to, SBT) is a well-known suppressor of 5-lypoxygenase as reported by Hamazaki's et al. SBT also has many other antiallergic and antiinflammatory effects. If we can use SBT tropically on bronchoallergic portions, we see the same phenomena occurring in in vivo and in vitro experiments.To obtain a high SBT concentration on the bronchoalligopathological portion, we sutudied kampo herb medicine, i.e., SBT inhalation therapy. After informed consent was obtained, 161 patients were divided into two groups (Group A, n = 81) (Group B, n = 80). Under the same conditions for different drugs, patients in group A inhaled SBT (500 μg/1 capsule, 4 times/day) for 3 years. Patients in group B inhaled sodium cromoglicate (CSCG) (20 mg/1 capsule) in the same administraton using DSCG-spinhela. The difference between DSCG and SBT in capsules was not recognized because these capsules were identical capsule using for DSCG, i.e., baseline clinical characteristics did not significantly differ between groups. At the end point, subjective symptoms such as asthmatic score, PEF titer, and resqure time of β 2 agonist use decreased significantly. Therapeutic drugs also decreased significantly in group A (p < 0.001). In group B, these parameters increased significantly. (p< 0.05). (p< 0.001 vs Group B) Adverse side effects and the appearance of abnormal laboratory data during this trial was lower in group A. In global improvement, group A showed 61.9%, but group B only 5.6% (p< 0.001). These reasons are discussed in this paper.

収録刊行物

• 耳鼻咽喉科展望

  耳鼻咽喉科展望 47 20-27, 2004

  耳鼻咽喉科展望会

キーワード

• 神秘湯
• 吸入療法
• 気管支喘息

詳細情報

• CRID: 1390001204952219776
• NII論文ID: 130003975310
• DOI: 10.11453/orltokyo1958.47.supplement1_20
• ISSN: 18836429
• ISSN: 03869687
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可